# US 2018/0022739 A1 · 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022739 A1
- Document ID: US20180022739A1
- Status: Published application
- Kind: A1
- Application number: 15/587,270
- Filed: 2017-05-04
- Published: 2018-01-25
- Earliest claimed: 2012-05-15
- Assignees: Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited
- Inventors: Ian Collins; Thomas Peter Matthews; Tatiana Faria Da Fonseca Mchardy; James Osborne; Michael Lainchbury; Michael Ian Walton; Michelle Dawn Garrett
- Web page: https://patentgrep.com/patent/US20180022739A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/02: containing two hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.

## Claims

### Claim at position 1

-66. (canceled)

### Claim 67

A compound according to formula II, or a salt, hydrate, or solvate thereof:
wherein
R3 is
where X is an alkyl or alkoxy organic functional group.

### Claim 68 (depends on 67)

The compound of claim 67, wherein X is selected from the group consisting of:
methyl (—CH3), benzyloxy (—OCH2C6H5), t-butoxy (—OC(CH3)3), 2-trimethylsilylethyloxy, and allyloxy.

### Claim 69 (depends on 67)

The compound of claim 67, wherein X is t-butoxy (—OC(CH3)3).

### Claim 70

A compound of formula III, or a salt, hydrate, or solvate thereof:
wherein
R3 is hydrogen or is
where X is an alkyl or alkoxy organic functional group.

### Claim 71 (depends on 70)

The compound of claim 70, wherein R3 is hydrogen.

### Claim 72 (depends on 70)

The compound of claim 70, wherein the compound is according to the following structure, or salt, hydrate, or solvate thereof:

### Claim 73

A process for manufacturing a compound according to the following structure, or a salt, hydrate, or solvate thereof:
wherein
R1 is CN;
R2 is CF3;
R3 is
where X is an alkyl or alkoxy organic functional group;
the process comprising using cross coupling reaction conditions to couple a compound of the structure:
to a compound of the structure:

### Claim 74 (depends on 73)

The process of claim 73, wherein the reaction conditions are as follows:
suspending: the
compound, the
compound, an organic phosphine compound, cesium carbonate, and a palladium(0) compound in an aprotic organic solvent;
and heating the suspension;
wherein R1, R2 and R3 are as defined in claim 73.

### Claim 75 (depends on 73)

The process of claim 73, wherein the heating is at about 100° C.

### Claim 76 (depends on 73)

The process of claim 73, wherein the heating lasts for about 24 hours.

### Claim 77 (depends on 73)

The process of claim 73, wherein R3 is

### Claim 78 (depends on 73)

The process of claim 73, wherein R3 is
